FINWIRES · TerminalLIVE
FINWIRES

CIBCはDefinity Financialの第1四半期決算をプレビューし、Travelersの買収が「大きな」影響を与えるだろうと述べた。

-- Definity FinancialによるTravelers Canadaの買収は四半期初めに完了し、CIBC Capital Marketsは、この買収が業績に大きな影響を与えると予想しています。 Definityは1月2日にTravelers Canadaの買収を完了しました。保険料収入は35%増加し、短期的には利益率の低下につながると見込まれています。アナリストのポール・ホールデン氏は、コストシナジー効果を除いた買収の財務的影響を、第1四半期の決算で初めて明らかにすると述べています。 ホールデン氏は、Definityの株価目標を74.00ドル、投資判断を「中立」に据え置いており、堅調な業績を期待しています。第1四半期の営業利益予想は0.88ドルで、市場コンセンサスの0.87ドルとほぼ一致しています。 ホールデン氏は、2026年のDefinityの成功は、Travelersの統合に大きく左右されると付け加えています。

Price: $66.93, Change: $-1.07, Percent Change: -1.57%

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF